Soft tissue leiomyosarcomas and malignant gastrointestinal stromal tumors: Differences in clinical outcome and expression of multidrug resistance proteins

Journal of Clinical Oncology

Volumn 18, Issue 18, 2000, Pages 3211-3220

  Plaat, Boudewijn E C ^a   Hollema H , Harry ^a   Molenaar W M , Willemina M ^a   Torn Broers G H , Gerben H ^a   Pijpe J , Justin ^a   Mastik M F , Mirjam F ^a   Hoekstra H J , Harald J ^a   Van den Berg, Eva ^a   Scheper R J , Rik J ^a   Van der Graaf W T A , Winette T A ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

MULTIDRUG RESISTANCE PROTEIN;

ABDOMINAL CAVITY INFLAMMATION; ARTICLE; CANCER SURVIVAL; GASTROINTESTINAL TUMOR; HUMAN; IMMUNOHISTOCHEMISTRY; LEIOMYOSARCOMA; MAJOR CLINICAL STUDY; METASTASIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SOFT TISSUE CANCER; TREATMENT OUTCOME;

EID: 0034666327     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2000.18.18.3211     Document Type: Article

References (79)

1. Epidemiological aspects of soft tissue sarcomas (STS): Consequences for the design of clinical trials
2. Gastrointestinal stromal tumors: Value of CD34 antigen in their identification and separation from true leiomyomas and schwannomas
3. Differentiation and risk assessment of gastrointestinal stromal tumors
4. Gastrointestinal stromal tumors
5. Subclassification of gastrointestinal stromal tumors based on evaluation by electron microscopy and immunohistochemistry
6. DNA copy number changes in gastrointestinal stromal tumors: A distinct genetic entity
7. Gastrointestinal sarcoma (GIST): A review of surgical management
8. Prognosis of gastrointestinal smooth-muscle (stromal) tumors: Dependence on anatomic site
9. Mutations in exon 11 of c-Kit occur preferentially in malignant versus benign gastrointestinal stromal tumors and do not occur in leiomyomas or leiomyosarcomas
10. Embryonic form of smooth muscle myosin heavy chain (SMemb/MHC-B) in gastrointestinal stromal tumor and interstitial cells of Cajal
11. Interstitial cells of Cajal as precursors of gastrointestinal stromal tumors
12. Gastrointestinal stromal tumors: Recent advances in understanding of their biology
13. Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors
14. Treatment of advanced, high-grade soft-tissue sarcoma with ifosfamide and continuous-infusion etoposide
15. Antitumor chemosensitivity differs between clinical sarcoma and adenocarcinoma tissues
16. High-dose ifosfamide: Circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas
17. Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcomas: An analysis of 2,185 patients treated with anthracycline-containing first-line regimens - A European Organization for Research and Treatment of Cancer soft tissue and bone sarcoma group study
18. Response to anthracycline based chemotherapy and overall survival in patients with lung metastases from soft tissue sarcoma: A retrospective study of the EORTC soft tissue and bone sarcoma group
19. Multidrug resistance in human cancer
20. P-glycoprotein in adult solid tumors: Expression and prognostic significance
21. P-glycoprotein, multidrug resistance and tumor progression
22. P-glycoprotein in human sarcoma: Evidence for multidrug resistance
23. Does P-glycoprotein predict response to chemotherapy?
24. Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome
25. Prevalence of multidrug resistance related to activation of the mdr1 gene in human sarcoma mutants derived by single-step doxorubicin selection
26. Expression of multidrug-resistance-associated protein gene in human soft-tissue sarcomas
27. Reverse transcriptase-polymerase chain reaction amplification of MDR1 gene expression in adult soft tissue sarcomas
28. Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs
29. Overlapping phenotypes of multidrug resistance among panels of human cancer-cell lines
30. Expression of multidrug resistance-associated protein gene in Ewing's sarcoma and malignant peripheral neuroectodermal tumor of bone
31. Immunochemical detection of the multidrug resistance-associated protein MRP in human multidrug-resistant tumor cells by monoclonal antibodies
32. The prognostic significance of expression of the multidrug resistance-associated protein (MRP) in primary breast cancer
33. Drug resistance-associated marker Lrp for prediction of response to chemotherapy and prognoses in advanced ovarian carcinoma
34. Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia
35. Expression of the lung resistance protein predicts poor outcome in de novo acute myeloid leukemia
36. Broad distribution of the multidrug resistance-related vault lung resistance protein in normal human tissues and tumors
37. Overexpression of a M(r) 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance
38. The drug resistance-related protein LRP is the human major vault protein
39. Reproducibility of a histopathologic grading system for adult soft tissue sarcoma
40. Reversal of Adriamycin resistance by verapamil in human ovarian cancer
41. Multifactorial drug resistance in an Adriamycin-resistant human small cell lung carcinoma cell line
42. Antigen retrieval in formalin fixed, paraffin embedded tissues: An enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections
43. Autoclave heating: An alternative method for microwaving?
44. Gastrointestinal stromal tumours
45. Contrast of response to D-MAP + Sargramostim between patients with advanced malignant gastrointestinal stromal tumors and patients with other advanced leiomyosarcomas
46. Hepatic metastases from soft-tissue sarcoma
47. A comparison of the prognoses for deep and subcutaneous sarcomas of the extremities
48. Intradermal and subcutaneous leiomyosarcoma: A clinicopathological and immunohistochemical study of 41 cases
49. Chemotherapy for bone and soft-tissue sarcomas of the extremities
50. Salvage therapy for soft tissue sarcomas
51. Randomized comparison of three Adriamycin regimens for metastatic soft tissue sarcomas
52. Results of single-agent and combination chemotherapy for advanced soft tissue sarcomas: Implications for decision making in the clinic
53. Results of two consecutive trials of dose-intensive chemotherapy with doxorubicin and ifosfamide in patients with sarcomas
54. High-dose therapy for adult soft tissue sarcoma: Dose response and survival
55. Ifosfamide-containing chemotherapy in Ewing's sarcoma: The Second United Kingdom Children's Cancer Study Group and the Medical Research Council Ewing's Tumor Study
56. Neoadjuvant chemotherapy for Ewing's sarcoma of bone: No benefit observed after adding ifosfamide and etoposide to vincristine, actinomycin, cyclophosphamide, and doxorubicin in the maintenance phase - Results of two sequential studies
57. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: A randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group
58. Distribution of multi-drug resistance-associated P-glycoprotein in normal and neoplastic human tissues: Analysis with 3 monoclonal antibodies recognizing different epitopes of the P-glycoprotein molecule
59. Tissue distribution of the multidrug resistance protein
60. Is the expression of multidrug resistance gene product a prognostic indicator for the clinical outcome of patients with renal cancer?
61. The P-glycoprotein multidrug transporter
62. Hepatocellular transport: Role of ATP-binding cassette proteins
63. Regulation of the multidrug resistance (MDR1) gene expression
64. Expression of the MDR1 gene in human gastric and colorectal carcinomas
65. Expression of MDR1 (multidrug resistance) gene and its protein in normal human kidney
66. Lung resistance protein (LRP) expression in human normal tissues in comparison with that of MDR1 and MRP
67. Immunohistochemical detection of P-glycoprotein: Prognostic correlation in soft tissue sarcoma of childhood
68. P-glycoprotein expression at diagnosis may not be a primary mechanism of therapeutic failure in childhood rhabdomyosarcoma
69. Prognostic implication of immunodetection of P glycoprotein in Ewing's sarcoma
70. P-glycoprotein expression in soft-tissue sarcomas
71. Evaluation of newer prognostic markers for adult soft tissue sarcomas
72. Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: Consensus recommendations
73. Flow cytometric analysis of P-glycoprotein expression and drug efflux in human soft tissue and bone sarcomas
74. CD117: A sensitive marker for gastrointestinal stromal tumors that is more specific than CD34
75. An immunohistochemical and clinicopathological study of gastrointestinal stromal tumors
76. Expression of c-kit (CD117) and Ki67 provides information about the possible cell of origin and clinical course of gastrointestinal stromal tumours
77. Expression of c-Kit and functional drug efflux are correlated in de novo acute myeloid leukaemia